Corporate Governance

Mr. Choi Ka Tsan Karson, was appointed as an executive Director and as the Chairman on 15 December 2023. Mr. Choi has been appointed as the Chief Executive Officer from 1 January 2024. Mr. Choi graduated from University of Southern California, the United States with a degree of bachelor of Arts in International Relations. Mr. Choi has been admitted to Honorary University Fellowship of the University of Hong Kong in October 2023.

Mr. Choi has been an independent non-executive director of Sing Tao News Corporation Limited (“Sing Tao”), a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 1105) since 2021 and has been redesignated as an executive director and the co-chairman with effect from 30 May 2022. Mr. Choi is currently the vice-chairman of Early Light Industrial Company Limited (“Early Light”), the founder and chairman of Unique Timepieces Watches Group Limited and the chairman of Fastwheel Motors Group Limited. Early Light is the world’s largest toys manufacturer. Under the leadership of Mr. Choi, Early Light has developed diversified businesses, including the industries of toys manufacturing, shopping mall development, property rental and management, luxury watches retail, motors sales and maintenance, bioplastic production and education.

Mr. Choi is a deputy director of The Population, Resources and Environment Committee of the Chinese People’s Political Consultative Conference and a member of the National Committee of the Chinese People’s Political Consultative Conference. Mr. Choi also serves as a member of the Court of the University of Hong Kong, members of various government advisory committees and leaders of social groups.

Dr. Fok Siu Wing Dominic, was appointed as an executive Director since 15 December 2023. Dr. Fok received a Bachelor of Medicine and Bachelor of Surgery from the University of Hong Kong in 1985, a Diploma in Family Medicine from The Chinese University of Hong Kong in 1992, and was admitted as a Fellow of the Royal Australian College of General Practitioners and a Fellow of the Hong Kong College of General Practitioners both in 1996. Dr. Fok has served in the Department of Community and Family Medicine (“DCFM”) of The Chinese University of Hong Kong, which was later merged with the School of Public Health to establish the School of Public Health and Primary Care (“SPHPC”) at The Chinese University of Hong Kong, successively as an honorary associate professor from 1996 to 1997, an adjunct assistant professor from 1997 to 2000 and from 2002 to 2003, an honorary clinical assistant professor from 2003 to 2007 and a clinical assistant professor (honorary) from 2007 to 2010. Since 2010, Dr. Fok has served as a clinical assistant professor (honorary) in SPHPC at The Chinese University of Hong Kong. Dr. Fok has served as an honorary clinical assistant professor in family medicine at the University of Hong Kong since 2014.

Dr. Fok is a registered doctor with the Medical Council of Hong Kong and has more than 30 years of practicing experience. Dr. Fok has served in the Group as a registered medical practitioner since 1999.

Ms. Zhang Xiaoxue, was appointed as an executive Director on 12 January 2024. Ms. Zhang obtained a master’s degree of Science in Finance (international money, finance and investment) from University of Durham in the United Kingdom in January 2014.

Ms. Zhang has approximately 9 years of experience in equity investment, financial management and risk management. Ms. Zhang is currently a deputy director of the investment management center in China Life Private Equity.

Ms. Zhang worked as an auditor in the audit department of KPMG Huazhen LLP （畢馬威華振會計師事務所（特殊普通合夥）） from October 2014 to October 2016. From October 2016 to August 2021, Ms. Zhang worked in the transaction advisory department of KPMG Advisory (China) Limited（畢馬威企業咨詢（中國）有限公司）, successively serving as assistant manager and manager. Since August 2021, Ms. Zhang has worked in China Life Private Equity, successively serving as senior manager and deputy director of the investment management center.

Mr. Huang Yu, was appointed as an executive Director on 24 February 2025. Mr. Huang graduated from Foreign Affairs College with a bachelor’s degree in laws majored in diplomacy and international relations in 2003. He also obtained a degree of master of business administration from INSEAD in 2008.

Mr. Huang worked as a section officer from September 2003 to August 2006 in China Life Insurance (Group) Company（中國人壽保險（集團）公司）, a substantial shareholder of the Company. He was a senior consultant in Value Partners Management Consulting（威普企業諮詢管理有限公司） from January 2009 to August 2011 and was an investment associate in Terra Firma Capital Partners Limited（泰豐資本控股有限公司） from September 2011 to April 2013. In addition, Mr. Huang has worked as a senior investment manager in China Life Investment Holdings Co., Ltd.（國壽投資控股有限公司） from May 2013 to September 2016 and a senior investment director in China Life Private Equity Investment Company Limited（國壽股權投資有限公司） from October 2016 to September 2022. Mr. Huang successively served as an investment director and the associate general manager of the Healthcare Investment Department and the associate general manager of Pension Finance Investment Department in China Life Healthcare Investment Company Limited（國壽健康產業投資有限公司） since October 2022. Mr. Huang has many years of experience in business investment, consultation and management.

Ms. Lee Wai Ling Linda , was appointed as a non-executive Director on 15 December 2023. Ms. Lee obtained a Bachelor of Arts from the University of Toronto in Canada in 1980, a Professional Diploma in Management and Marketing for Business Events from the Hong Kong Productivity Council and the Hong Kong Exhibition & Convention Industry Association Limited in 2003 and a Master of Science in Human Resources Management and Development from the University of Leicester in the United Kingdom in 2013.

Ms. Lee has extensive experience in corporate human resources and corporate management. Ms. Lee has served as a vice president of responsible sourcing in BioLogiQ Elite (HK) Ltd. since 4 June 2019. Ms. Lee served the Vocational Training Council from October 1998 to March 2019 with her last position as the deputy head of the human resources division, and the personnel and administration manager of Early Light from June 1995 to June 1997.

Ms. Lau Suk Hing Clara, was appointed as a non-executive Director since 15 December 2023. Ms. Lau has served Early Light International (Holdings) Limited (“Early Light International”) since June 1992. She has served as the personal assistant to the chairman of Early Light International and also serves as a director of several companies of Early Light International in Hong Kong and Mainland China.

Ms. Lau has extensive experience in assisting the chairman of Early Light International in handling the group’s real estate development, manufacturing and retail businesses for many years, including internal supervision, finance and general daily management and operations.

Mr. Liu Yang, was appointed as a non-executive Director on 12 January 2024. Mr. Liu obtained a bachelor’s degree in Economics from University of International Business and Economics（對外經濟貿易大學） in July 2002. Mr. Liu is a non-practicing member of the Chinese Institute of Certified Public Accountants, a member of CPA Australia and has been awarded the professional designation of Certified Internal Auditor by The Institute of Internal Auditors.

Mr. Liu has over 20 years of experience in equity investment, financial management and risk management. Mr. Liu is currently the deputy general manager of China Life Private Equity Investment Company Limited (“China Life Private Equity”), and serves as a director and/or supervisor in several subsidiaries of China Life Private Equity. 

Mr. Liu worked in the audit department of KPMG Huazhen LLP （畢馬威華振會計師事務所（特殊普通合夥）） from August 2002 to March 2011, where he successively worked as auditor, assistant manager, manager, and senior manager. From March 2011 to May 2011, Mr. Liu served as the chief financial officer in Beijing Yuanjing Hokay Sports Development Co., Ltd. （北京遠景浩泰體育發展有限公司）. From May 2011 to February 2017, Mr. Liu  worked in China Mobile Finance Co., Ltd. （中國移動通信集團財務有限公司）, where he successively held various positions including project manager in the special project preparatory group, project manager in the risk management department, deputy general manager, general manager, deputy general manager of the audit and compliance department and supervisor. Since February 2017, Mr. Liu worked in China Life Private Equity, successively working as the chief director and the person in charge of the investment management center, the person in charge of the financial management center, management committee member, and deputy general manager.

From January 2021 to October 2022, Mr. Liu served as a director in Goodwill E-Health Info Co., Ltd. （嘉和美康（北京）科技股份有限公司） (a company listed on the Shanghai Stock Exchange (stock code: 688246)); and from December 2020 to January 2022, Mr. Liu served as a director in Dareway Software Co., Ltd. （山大地緯軟件股份有限公司）(a company listed on the Shanghai Stock Exchange (stock code:688579)).

Ms. Zhang Leidi, was appointed as a non-executive Director on 12 January 2024. Ms. Zhang obtained a master’s degree in economics from Peking University in July 2003.

Ms. Zhang has over 20 years of experience in equity investment and project management. Ms. Zhang is currently the vice-president (presiding over the work) （副總經理（主持工作）） of China Life Private Equity Investment Company Limited (“China Life Private Equity”), and serves as a director and/or supervisor in several subsidiaries of China Life Private Equity.

Ms. Zhang worked in Roland Berger Strategy Consultants from July 2003 to February 2010, where she successively worked as consultant, senior consultant and project manager. From March 2011 to September 2011, she worked as a part-time consultant in Roland Berger Strategy Consultants. From October 2011 to September 2016, Ms. Zhang worked in China Life Investment Holdings Co., Ltd. （國壽投資控股有限公司）, where she successively worked as senior manager, investment director and senior investment director of the direct investment department. Since October 2016, Ms. Zhang has worked in China Life Private Equity, successively working as managing director, chairperson of management committee and vice-president (presiding over the work) （副總經理（主持工作））.

From March 2019 to April 2022, Ms. Zhang was a director of Bloomage Biotechnology Corporation Limited（華熙生物科技股份有限公司） (a company listed on the Shanghai Stock Exchange (stock code: 688363)); from March 2020 to May 2023, Ms. Zhang was a director of Nanjing Vazyme Biotech Co., Ltd. （南京諾唯贊生物科技股份有限公司） (a company listed on the Shanghai Stock Exchange (stock code: 688105)); from September 2020 to August 2023, Ms. Zhang was a director of Shanghai United Imaging Healthcare Co., Ltd. （上海聯影醫療科技股份有限公司） (a company listed on the Shanghai Stock Exchange (stock code: 688271)); and since November 2022, Ms. Zhang has been a non-executive director of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. （百奧賽圖（北京）醫藥科技股份有限公司） (a company listed on the Main Board of the Stock Exchange (stock code: 02315)).

Mr. Yu, has been appointed as an independent non-executive Director since June 2015. Mr. Yu graduated from The Fourth Military Medical University（第四軍醫大學）in 1984. He obtained a master degree in medicine from 中國協和醫科大學 (in English for identification purpose only, China Union Medical University) (now known as Peking Union Medical College（北京協和醫學院）) in 1991. Mr. Yu is currently an assistant to the medical superintendent, a professor in emergency medicine and a supervisor of the emergency medicine division of Peking Union Medical College Hospital（北京協和醫院）. He is also the chairman of 中國醫師協會急診醫學分會 (in English for identification purpose only, The Society of Emergency Medicine of Chinese Medical Doctor Association) and the chairman of 中華醫學會急診醫學分會 (in English for identification purpose only, The Society of Emergency Medicine of Chinese Medical Association). Mr. Yu has profound knowledge and extensive experience in teaching, scientific research and clinical experience in emergency medicine. Mr. Yu is also a member of each of the Audit Committee, the Nomination Committee and the Remuneration Committee.

Dr. Xu, has been appointed as independent non-executive director from 31st March 2021. Dr. Xu graduated from Harbin Medical University（哈爾濱醫科大學）in 1980 and obtained the master degree in medicine from Shanghai Jiao Tong University School of Medicine （上海交通大學醫學院） (formerly known as Shanghai Second Medical University（上海第二醫科大學）) in 1993 and the doctoral degree in management from Tongji University（同濟大學）in 2004. Dr. Xu was qualified as a Chief Physician by Shanghai Jiao Tong University School of Medicine (formerly known as Shanghai Second Medical University) in 2000. Dr. Xu has solid theoretical foundation and profound practical experience in clinical medicine and hospital management. Dr. Xu is a former dean of the Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine（上海交通大學醫學院附屬新華醫院）. He has also been a doctoral adviser of Shanghai Jiao Tong University. Dr. Xu is currently the chairman of Health Management Branch of China Association of Medical Equipment（中國醫學裝備協會健康管理分會）, a researcher of the Academic Committee of China Academy of Management Sciences（中國管理科學研究院學術委員會）and a researcher of the Health Policy Research Center of Shanghai Jiao Tong University（上海交通大學衞生政策研究中心）. Dr. Xu was formerly a director of the Graduate School of Strategic Management of China Hospital Development Institute （中國醫院發展研究院醫院戰略管理研究所）, a member of the Academic Committee of the Research Center for Healthcare Management of School of Economics and Management of Tsinghua University（清華大學經濟管理學院醫療管理研究中心學術顧問委員會）and a final evaluation expert of the “2009 Chinese Medical Science and Technology Award”*（2009年中華醫學科技獎）. Dr. Xu was awarded the “Xian Sheng Cup” – “Outstanding Dean of Hospitals in China”* （中國醫院“先聲杯”優秀院長）by the Chinese Hospital Association （中國醫院協會） in 2010 and the “Hua Ren Cup 2011 – Dean of Best Leadership of Hospitals in China”* （“華仁杯”2011最具領導力中國醫院院長）by the China Hospital CEO Magazine（中國醫院院長雜誌社） in 2011.

Mr. Han Wenxin, was appointed as an independent non-executive Director on 15 August 2022. Mr. Han obtained a degree of Bachelor of Arts from the University of International Relations in July 1997 and obtained a degree of Master of Science in International Business from the University of Nottingham in December 2007. Mr. Han has been the chairman of CCD Strategy Limited since September 2019. Mr. Han has also been the executive director of Shanghai Hehuang Medical Technology Co., Ltd. Since December 2020. Mr. Han is a vice chairman of Hainan Saint Apricot Medical Development Foundation.

Mr. Chan Wai Kan, was appointed as an independent non-executive Director on 15 December 2023. Mr. Chan holds a Bachelor of Science degree in Economics & Accountancy from City, University of London, United Kingdom, as well as a Master of Business Administration from The Chinese University of Hong Kong. He is a member of both the Institute of Chartered Accountants in England and Wales and The Hong Kong Institute of Certified Public Accountants.

With an extensive background spanning over three decades in financial management, Mr. Chan currently holds the position of executive director at Shui On Investment Company Limited. Additionally, starting from September 1, 2023, he has assumed the role of non-executive director at SOCAM Development Limited, a Main Board-listed company on the Stock Exchange (stock code: 983). 

Throughout his professional journey, Mr. Chan has been grateful for the valuable opportunities he has had to make contributions in senior management roles across diverse industries, including real estate development and investment, toy development and marketing, and magazine publishing.

Mr. Cheung Ka Ming, was appointed as an independent non-executive Director on 15 December 2023. Mr. Cheung received a Bachelor of Science degree from the University of Hong Kong in 1983 and a Master of Business Administration from the City University, London, United Kingdom in 1989.

Mr. Cheung is experienced in investment and financial services from his previous services in local and multinational financial institutions.

Mr. Tsui Wing Cheong Sammy, was appointed as an independent non-executive Director on 15 December 2023. Mr. Tsui obtained a Master of Business Administration from The Chinese University of Hong Kong. He was also a mentor in the HKU Media Mentorship Program at the Journalism and Media Studies Center of the University of Hong Kong.

Mr. Tsui founded China Tech Global Limited (now known as China Tech Global (Holdings) Limited) (“China Tech”) in 2014 and then started to run the sanitizing business under BioEm Air Sanitizing Technology Company Limited, which is a subsidiary of China Tech.

Mr. Tsui founded Golden Wealth Technology Limited (“Golden Wealth”) in March 2020, and Golden Wealth became the SenseTime innovation partner and the distributor in Hong Kong and Macau of SenseTime Group Limited. Golden Wealth is engaged in provision of artificial intelligence solutions. The clients of Gloden Wealth include Disciplined Services and major infrastructures in Hong Kong.

Mr. Tsui was appointed as an executive director and deputy chief executive officer of Celestial Asia Securities Holdings Limited, a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 1049), with effect from October 2013 and was appointed as the chief executive officer of Celestial Asia Securities Holdings Limited with effect from January 2014 to July 2014. Mr. Tsui was an executive director and the chief executive officer of China Outdoor Media Group Limited (now known as National United Resources Holdings Limited), a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 254), from April 2011 to September 2013.

Mr. Mr. Lo Wai Keung Eric, has been appointed as the Company Secretary, the Authorised Representative and the Process Agent since 18 June 2024. Mr. Lo was admitted as a solicitor of the High Court of Hong Kong in 2006. Prior to joining the Company, Mr. Lo worked in an international law firm in Hong Kong, specializing in mergers and acquisitions, listing rules compliance and other corporate finance matters. Mr. Lo possesses more than 17 years of experience in corporate and commercial legal work.